CSIMarket
 


Chelsea Therapeutics International, Ltd.  (CHTP)
Other Ticker:  
 

Chelsea Therapeutics International Ltd.'s Working Capital Ratio

CHTP's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


In the wake of the increase in Current Liabilities in the first quarter 2014, Working Capital Ratio fell to 16.29 above Chelsea Therapeutics International, Ltd. average.

Within Biotechnology & Pharmaceuticals industry 25 other companies have achieved higher Working Capital Ratio than Chelsea Therapeutics International Ltd. in first quarter 2014. While Working Capital Ratio total ranking has improved so far during the I Quarter 2014 to 320, from total ranking in the forth quarter 2013 at 322.

Explain Working Capital Ratio
How much in Current Assets CHTP´s has?
What is the value of CHTP´s Current Liabilities?


CHTP Working Capital Ratio (Mar 31 2014)
I. Quarter
(Dec 31 2013)
IV. Quarter
(Sep 30 2013)
III. Quarter
(Jun 30 2013)
II. Quarter
(Dec 31 2012)
IV. Quarter
Y / Y Current Liabilities Change 58.48 % -53.28 % -74.7 % - -
Y / Y Current Assets Change 33.22 % 38.16 % -47.61 % - -
Working Capital Ratio MRQ 16.29 23.84 11.89 14.76 19.38
CHTP's Total Ranking # 320 # 322 # 320 # 313 #
Seq. Current Liabilities Change 20.74 % 4.98 % 21.87 % 2.59 % -64.41 %
Seq. Current Assets Change -17.49 % 110.39 % -1.78 % -21.87 % -14.42 %



Working Capital Ratio first quarter 2014 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 26
Healthcare Sector # 92
Overall Market # 320


Working Capital Ratio Statistics
High Average Low
23.84 14.28 5.74
(Dec 31 2013)   (Jun 30 2012)




Financial Statements
Chelsea Therapeutics International Ltd.'s Current Liabilities $ 2 Millions Visit CHTP's Balance sheet
Chelsea Therapeutics International Ltd.'s Current Assets $ 38 Millions Visit CHTP's Balance sheet
Source of CHTP's Sales Visit CHTP's Sales by Geography


Cumulative Chelsea Therapeutics International Ltd.'s Working Capital Ratio

CHTP's Working Capital Ratio for the trailling 12 Months

CHTP Working Capital Ratio

(Mar 31 2014)
I. Quarter
(Dec 31 2013)
IV. Quarter
(Sep 30 2013)
III. Quarter
(Jun 30 2013)
II. Quarter
(Dec 31 2012)
IV. Quarter
Y / Y Current Liabilities TTM Growth 58.48 % -53.28 % -74.7 % - -
Y / Y Current Assets TTM Growth 33.22 % 38.16 % -47.61 % - -
Working Capital Ratio TTM 16.84 17.58 11.84 8.75 8.04
Total Ranking TTM # 71 # 2828 # 0 # 0 #
Seq. Current Liabilities TTM Growth 20.74 % 4.98 % 21.87 % 2.59 % -64.41 %
Seq. Current Assets TTM Growth -17.49 % 110.39 % -1.78 % -21.87 % -14.42 %


On the trailing twelve months basis Due to growth in Current Liabilities in the I Quarter 2014 to $2.35 millions, cumulative Working Capital Ratio decreased to 16.84 above the CHTP average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 2 other companies have achieved higher Working Capital Ratio than Chelsea Therapeutics International Ltd.. While Working Capital Ratio overall ranking has improved so far to 71, from total ranking during the twelve months ending forth quarter 2013 at 2828.

Explain Working Capital Ratio
How much in Current Assets CHTP´s has?
What is the value of CHTP´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 3
Healthcare Sector # 11
Within the Market # 71


trailing twelve months Working Capital Ratio Statistics
High Average Low
17.58 12.54 8.75
(Dec 31 2013)   (Jun 30 2013)




Companies with similar Working Capital Ratio in the quarter ending Mar 31 2014, within Biotechnology & Pharmaceuticals Industry Working Capital RatioMar 31 2014 MRQ Current AssetsMar 31 2014 MRQ Current Liabilities
Eiger Biopharmaceuticals Inc   33.19 $ 58.214  Millions$ 1.754  Millions
Nutrastar International Inc.  33.15 $ 105.722  Millions$ 3.190  Millions
Organovo Holdings Inc   25.97 $ 49.161  Millions$ 1.893  Millions
Acceleron Pharma inc  23.88 $ 219.366  Millions$ 9.188  Millions
Genocea Biosciences Inc   21.86 $ 66.940  Millions$ 3.062  Millions
Neurocrine Biosciences Inc   20.90 $ 221.735  Millions$ 10.608  Millions
Aerie Pharmaceuticals Inc   17.83 $ 65.783  Millions$ 3.690  Millions
Fresh Tracks Therapeutics Inc   16.61 $ 55.348  Millions$ 3.333  Millions
Armata Pharmaceuticals Inc   16.37 $ 16.792  Millions$ 1.026  Millions
Chelsea Therapeutics International, Ltd.  16.29 $ 38.334  Millions$ 2.353  Millions
Iovance Biotherapeutics Inc   16.28 $ 18.068  Millions$ 1.110  Millions
Enzon Pharmaceuticals inc   16.01 $ 14.918  Millions$ 0.932  Millions
Sangamo Therapeutics Inc   13.65 $ 220.212  Millions$ 16.131  Millions
Aceragen Inc   13.41 $ 71.804  Millions$ 5.354  Millions
Bio techne Corp  13.11 $ 319.531  Millions$ 24.364  Millions
Repligen Corp  12.45 $ 88.697  Millions$ 7.122  Millions
Momenta Pharmaceuticals inc   12.45 $ 239.097  Millions$ 19.200  Millions
Applied Genetic Technologies Corporation  11.77 $ 25.583  Millions$ 2.174  Millions
Cannabis Global Inc.  11.53 $ 0.070  Millions$ 0.006  Millions
Cardiff Oncology inc   11.45 $ 23.263  Millions$ 2.032  Millions
Fate Therapeutics Inc   11.30 $ 48.263  Millions$ 4.272  Millions
Pharmacyte Biotech Inc   11.20 $ 4.187  Millions$ 0.374  Millions
Pluri Inc   10.04 $ 64.709  Millions$ 6.442  Millions
Receptos, Inc.  9.87 $ 160.477  Millions$ 16.259  Millions
Novavax inc  9.40 $ 128.873  Millions$ 13.715  Millions
Curis Inc   8.30 $ 59.648  Millions$ 7.184  Millions
Palisade Bio Inc   7.30 $ 34.109  Millions$ 4.674  Millions
Bluebird Bio Inc   7.03 $ 195.920  Millions$ 27.856  Millions
Eloxx Pharmaceuticals Inc   7.01 $ 7.398  Millions$ 1.055  Millions
Windtree Therapeutics Inc  6.90 $ 76.817  Millions$ 11.135  Millions

Date modified: -0001-11-30T00:00:00+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com